We are pleased to announce a new project, funded by the Laura and John Arnold Foundation, to identify unnecessary, wasteful, or inefficient care in the US. The project, led by David Kim, PhD, will build on other work in this area by using CEVR’s
Cost-Effectiveness Analysis CEA) Registry
and a database on commercially-insured populations to quantify the greatest disinvestment opportunities.
In other news, we highlight research on the benefits and costs of gene therapies, health utilities in autism, the cost-effectiveness of nutrition policies on processed meat, and variation in how US payers are covering orphan drugs, a project using CEVR’s
Specialty Drug Evidence and Coverage (SPEC)
database.
Happy Thanksgiving!
Peter Neumann, ScD
Director, Center for the Evaluation of Value and Risk in Health
Institute for Clinical Research and Health Policy Studies
Tufts Medical Center
|
|
Peter Neumann, ScD,
talks to NPR's Carey Goldberg
about the role of the Institute for Clinical and Economic Review (ICER) in the fight to lower American drug prices.
|
|
On this episode of AJMC TV
,
James Chambers, PhD,
discusses variability in specialty drug coverage and its impact based on his analysis of CEVR's SPEC Database.
|
|
A study by
James Chambers, PhD,
using the SPEC Database is featured in
Forbes'
examination of the use of step therapy for prescription drugs.
|
|
The
CEA Registry
has been updated to include all cost-per-QALY studies published through 2018.
|
|
Thanks to our
2019 CEVR Summer Interns
who read and extracted extensive data from more than 300 new articles that were added to
the CEA Registry as part of this update!
|
|
2019 Cost-Effectiveness Analysis Paper of the Year
|
|
|
|
Submissions are open for CEVR's
2019 Cost-Effectiveness Analysis (CEA) Paper of the Year Award
. Policy makers are increasingly seeking evidence on the value of health care to inform clinical guidelines and reimbursement decisions. CEVR's award will highlight this important research and promote findings to a broad audience.
Visit
our website
to learn more about criteria, the selection process, and to submit or recommend a paper.
|
|
Members of CEVR's Global Health Team,
David Kim, PhD, Rachel Bacon, MPH, and Peter Neumann, ScD
, authored a chapter, “Assessing the Transferability of Economic Evaluations: A Decision Framework” in the upcoming book
Non-Communicable Disease Prevention: Best Buys, Wasted Buys, and Contestable Buys
- a thinking aid for achieving best value for money in NCD prevention, published by Open Book Publishers.
|
|
Funded by a three-year grant from the PhRMA Foundation, CEVR has established a new Center:
The Center for Enhanced Value Assessment (CEVA). Under this grant, CEVA researchers conducted an analysis of over 8,000 studies in the CEA and Global Health CEA Registries to determine how often published CEAs included cost components beyond those traditionally included in a health-sector perspective (see box).
|
|
New CEVA research:
- Most published CEAs do not include a societal perspective
- The most commonly included non-healthcare cost in cost-per-QALY studies is productivity, whereas in the cost-per-DALY literature, it is patient transportation costs
- Next, CEVA will produce case studies incorporating broader elements of value into existing CEA models
|
|
Paige Lin, PhD,
recently presented
her work at The National Academy of Medicine examining
health economics and public policy issues in Alzheimer’s disease and related dementias.
|
|
James Chambers, PhD,
presented his research on the QALY gains offered by gene therapies at the ISPOR Israel Chapter Meeting in October.
|
|
Congratulations to CEVR Associate Professors
Paige Lin, PhD
, (far left) and
James Chambers, PhD
(fourth from left),
who recently celebrated ten years at CEVR!
|
|
Congratulations to
Natalia Olchanski, PhD
, Research Assistant Professor, who completed her PhD in Clinical and Translational Science from Tufts University.
|
|
Using data from the
CEA Registry
, CEVR Director,
Peter Neumann, ScD
, presented "Measuring the value of prescription drugs: The latest from the US," at the Health and Healthcare in the Age of Innovation Conference in Jerusalem in September.
|
|
CEVR Director of Value Measurement & Global Health Initiatives,
Dan Ollendorf, PhD
,
presented
strategies to reduce low-value health care
at the
Health Affairs' forum on Health Spending
in Washington, DC in September.
|
|
Allan Daly, MS
Data Scientist
Allan assists in data management and statistical analyses for health economics and outcomes research. Allan received his MS in Healthcare Research from Dartmouth in 2019 and a BA in Mathematics and Classics from Augustana College in 2018.
|
|
Lauren Do, BA
Research Assistant
Lauren’s research focuses on using clinical and economic evidence to evaluate the prevalence of low-value healthcare services. Lauren graduated from Tufts University in 2019 with a BS in Quantitative Economics and Philosophy.
|
|
Marlena Keisler, BS
Research Assistant
Marlena's research focuses on how next generation sequencing techniques shorten the diagnostic odyssey, and on surveying patient preferences for managing major depressive disorder. Marlena graduated from the University of Massachusetts, Amherst in 2019 with a BS in Biology.
|
|
Siyu Ma, PhD
Post-Doctoral Research Fellow
Funded by GlaxoSmithKline, Siyu's research focuses on vaccines. Her doctoral dissertation studied the impact of cost containment strategies on adherence and the association between utilization and costs among breast cancer patients. She holds a PhD in Health Policy and an MBA/MS in Healthcare Management from Brandeis University.
|
|
Follow CEVR on Twitter and LinkedIn for the latest CEA news and insights!
|
|
|
|
|
|
|
